# Epigenetic context defines the transcriptional activity of canonical and noncanonical NF-κB signaling in pancreatic cancer

**Authors:** Joana E. Aggrey-Fynn, Joshua Busch, Dominik Saul, Ashish Rajput, Kerstin Willecke, Meghana Manjunath, Nicole Klimt, Kothai Rajendran, Nadine Schacherer, Wanwan Ge, Julia Thiel, Amro Abdelrahman, Mark J. Truty, Meng Dong, Steven A. Johnsen

PMC · DOI: 10.1038/s41420-026-03019-9 · Cell Death Discovery · 2026-03-17

## TL;DR

This study explores how two NF-κB signaling pathways, controlled by RELA and RELB, are activated differently in pancreatic cancer and affect gene expression.

## Contribution

The study reveals distinct regulatory roles of RELA and RELB in pancreatic cancer, linked to chromatin accessibility and co-regulation with AP1.

## Key findings

- TNFα activates canonical NF-κB via RELA, while TWEAK activates noncanonical signaling via RELB in pancreatic cancer.
- RELA binds to both open and closed chromatin, whereas RELB binds only to pre-accessible chromatin enriched with AP1 motifs.
- RELA and RELB show distinct spatial and cellular activity patterns in tumor and microenvironment compartments.

## Abstract

NF-κB signaling can be subdivided into canonical and noncanonical pathways, culminating in the transcriptional activity of RELA and RELB, respectively. However, the upstream signals that activate these transcription factors and their specific regulatory roles in pancreatic ductal adenocarcinoma (PDAC) remain incompletely understood. We investigated the differential activation and function of RELA and RELB in PDAC using transcriptome-wide gene expression profiling, genome-wide occupancy mapping, and epigenomic analysis. Temporal activation patterns were assessed following TNFα or TWEAK stimulation. Single-cell RNA sequencing and multiplex immunofluorescence staining were used to characterize activity in primary PDAC tissues. Motif enrichment and chromatin accessibility were evaluated to determine transcription factor binding dynamics and co-regulatory associations. We demonstrate that TNFα is the primary activator of canonical NF-κB signaling via RELA, while TWEAK selectively engages noncanonical signaling through RELB in PDAC. RELA and RELB display distinct temporal dynamics and regulatory activity. RELA binds to both open and closed chromatin and drives a broad transcriptional program, while RELB exclusively occupies pre-accessible chromatin regions co-enriched for AP1 motifs. Motif analysis reveals a particularly strong association of RELB with AP1 elements, suggesting selective co-regulation. Single-cell transcriptomic analysis and multiplex staining in primary tumors reveal distinct spatial and cellular distribution patterns, with RELA and RELB active in separate tumor and microenvironmental compartments. These findings underscore the distinct and complementary roles of TNFα and TWEAK in regulating NF-κB signaling in PDAC. TNFα engages a broader transcriptional program via RELA, whereas TWEAK targets a more selective set of genes marked by chromatin accessibility and AP1 co-binding through RELB. This study provides critical insight into the regulatory dynamics of NF-κB signaling in pancreatic cancer and highlights the specialized functions of RELA and RELB in modulating gene expression and tumor-microenvironment interactions.

## Linked entities

- **Genes:** RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970], RELB (RELB proto-oncogene, NF-kB subunit) [NCBI Gene 5971], FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353]
- **Diseases:** pancreatic ductal adenocarcinoma (MONDO:0005184)

## Full-text entities

- **Genes:** ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, NFKB2 (nuclear factor kappa B subunit 2) [NCBI Gene 4791] {aka CVID10, H2TF1, LYT-10, LYT10, NF-kB2, p100}, RELB (RELB proto-oncogene, NF-kB subunit) [NCBI Gene 5971] {aka I-REL, IMD53, IREL, REL-B}, Rela (Rela proto-oncogene, NFKB subunit) [NCBI Gene 19697] {aka p65, p65 NF-kappa B, p65 NFkB}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TNFSF13B (TNF superfamily member 13b) [NCBI Gene 10673] {aka BAFF, BLYS, CD257, TALL-1, TALL1, THANK}, Nfkb2 (nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100) [NCBI Gene 18034] {aka NF-kappaB2, lyt, p49, p49/p100, p50B, p52}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, MCL1 (MCL1 apoptosis regulator, BCL2 family member) [NCBI Gene 4170] {aka BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, Mcl-1}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, MAP3K14 (mitogen-activated protein kinase kinase kinase 14) [NCBI Gene 9020] {aka FTDCR1B, HS, HSNIK, IMD112, NIK}, BCL3 (BCL3 transcription coactivator) [NCBI Gene 602] {aka BCL4, D19S37}, TNFRSF1B (TNF receptor superfamily member 1B) [NCBI Gene 7133] {aka CD120b, TBPII, TNF-R-II, TNF-R75, TNFBR, TNFR1B}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, XIAP (X-linked inhibitor of apoptosis) [NCBI Gene 331] {aka API3, BIRC4, IAP-3, ILP1, MIHA, XLP2}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, TNFAIP3 (TNF alpha induced protein 3) [NCBI Gene 7128] {aka A20, AIFBL1, AISBL, OTUD7C, TNFA1P2}, FOSL1 (FOS like 1, AP-1 transcription factor subunit) [NCBI Gene 8061] {aka FRA, FRA1, fra-1}, TNFRSF25 (TNF receptor superfamily member 25) [NCBI Gene 8718] {aka APO-3, DDR3, DR3, LARD, TNFRSF12, TR3}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, TNFRSF12A (TNF receptor superfamily member 12A) [NCBI Gene 51330] {aka CD266, FN14, TWEAKR}, TRAF3 (TNF receptor associated factor 3) [NCBI Gene 7187] {aka CAP-1, CD40bp, CRAF1, IIAE5, IMD132A, IMD132B}, Relb (Relb proto-oncogene, NFKB subunit) [NCBI Gene 19698] {aka shep}, CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, TNFSF11 (TNF superfamily member 11) [NCBI Gene 8600] {aka CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, REL (REL proto-oncogene, NF-kB subunit) [NCBI Gene 5966] {aka C-Rel, HIVEN86A, IMD92}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, EFNA1 (ephrin A1) [NCBI Gene 1942] {aka B61, ECKLG, EPLG1, GMAN, LERK-1, LERK1}, Tpx2 (TPX2, microtubule-associated) [NCBI Gene 72119] {aka 2610005B21Rik, DIL2, REPP86, p100}, TNFSF12 (TNF superfamily member 12) [NCBI Gene 8742] {aka APO3L, DR3LG, TNF12, TNLG4A, TWEAK}
- **Diseases:** PDAC (MESH:D021441), metastasis (MESH:D009362), PAAD (MESH:D010190), epithelial tumor (MESH:D002277), cystic, mucinous, and serous adenocarcinomas (MESH:D018297), Tumor Diseases (MESH:D009369), chronic (MESH:D002908), inflammation (MESH:D007249), RBCT (MESH:C535687)
- **Chemicals:** AMPure (-), poly-A (MESH:D011061), Sepharose (MESH:D012685), streptomycin (MESH:D013307), L-Glutamine (MESH:D005973), staurosporine (MESH:D019311), DAPI (MESH:C007293), phenol red (MESH:D010637), CHX (MESH:D003513), Penicillin (MESH:D010406)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** CVCL_0152 — Homo sapiens (Human), Transformed cell line (CVCL_K421), AsPC-1 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0152), L3.6pl — Homo sapiens (Human), Pancreatic adenosquamous carcinoma, Cancer cell line (CVCL_0384), CVCL_0384 — Homo sapiens (Human), Transformed cell line (CVCL_8Z62)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13039881/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13039881/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC13039881/full.md

---
Source: https://tomesphere.com/paper/PMC13039881